Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:59 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 13,609 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Terminated No phase listed Observational

The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture

NCT00481585
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

NCT01353976
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Foam 1%, Vehicle Foam
Drug · Other
Lead sponsor
AmDerma
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Nov 2, 2026, 6:59 PM EST
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 2, 2026, 6:59 PM EST
Completed Not applicable Interventional

Inspiratory Muscle Training in Obese Breast Cancer Survivors

NCT05193149
View directory record Official record
Conditions
Cancer Survivors, Obesity, Breast Cancer
Interventions
Inspiratory muscle training, Exercise training
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 2, 2026, 6:59 PM EST
Active, not recruiting Phase 3 Interventional Results available

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338
View directory record Official record
Conditions
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
1,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 2 Interventional Results available

Xeloda (Capecitabine) and External Beam Radiation

NCT00916578
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy, Capecitabine
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Nov 2, 2026, 6:59 PM EST
Not listed Phase 2 Interventional

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

NCT02142335
View directory record Official record
Conditions
Malignant Melanoma of Skin Stage III, Metastatic Melanoma
Interventions
Rituxan
Drug
Lead sponsor
California Cancer Assocaties for Research & Excellence
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Nov 2, 2026, 6:59 PM EST
Withdrawn No phase listed Observational

Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry

NCT02427308
View directory record Official record
Conditions
Leishmaniasis or Other Uses of Miltefosine
Interventions
Miltefosine
Drug
Lead sponsor
Knight Therapeutics (USA) Inc
Industry
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
North Potomac, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 1 Interventional

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00003548
View directory record Official record
Conditions
Cancer
Interventions
aminocamptothecin colloidal dispersion
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 3 Interventional

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Nov 2, 2026, 6:59 PM EST
Completed No phase listed Observational Accepts healthy volunteers

The Lipid Profile of the Skin Surface in Acne

NCT02180425
View directory record Official record
Conditions
Acne
Interventions
Tretinoin or Adapalene, Isotretinoin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Davis, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 2, 2026, 6:59 PM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

NCT01041625
View directory record Official record
Conditions
Lichen Planus
Interventions
Apremilast (CC-10004)
Drug
Lead sponsor
Virginia Clinical Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2010 · Synced Nov 2, 2026, 6:59 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

3D Ultrasound Microvessel Imaging for Breast Masses

NCT04925817
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Ultrasound Microvessel Imaging
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Nov 2, 2026, 6:59 PM EST
Terminated Phase 2 Interventional Results available

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

NCT00810017
View directory record Official record
Conditions
HER-2 Positive Metastatic Breast Cancer
Interventions
Etoposide, Trastuzumab
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Nov 2, 2026, 6:59 PM EST
Withdrawn No phase listed Observational

Breast Cancer BRCA1 Carriers: a Pilot Study

NCT05062174
View directory record Official record
Conditions
BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
Mifepristone 200 MG, Prophylactic mastectomy
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Nov 2, 2026, 6:59 PM EST
Completed Not applicable Interventional

Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer

NCT01698658
View directory record Official record
Conditions
Breast Cancer
Interventions
ultrasound tomography, magnetic resonance imaging
Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 4 Interventional Results available

Combination Therapy for Atopic Dermatitis

NCT00119158
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Combination of pimecrolimus and fluticasone, pimecrolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Nov 2, 2026, 6:59 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

NCT01116648
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 2, 2026, 6:59 PM EST
Terminated Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer

NCT00088985
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

NCT00733408
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
17
States / cities
Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Nov 2, 2026, 6:59 PM EST
Withdrawn Phase 3 Interventional

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

NCT04128176
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
Rituximab combined with Omalizumab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 1 Interventional

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

NCT04132817
View directory record Official record
Conditions
Breast Cancer
Interventions
Nivolumab, Ipilimumab, Nab-paclitaxel
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

NCT01325350
View directory record Official record
Conditions
Alopecia, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Nov 2, 2026, 6:59 PM EST
Completed Phase 2 Interventional Results available

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)

NCT00503750
View directory record Official record
Conditions
Breast Cancer
Interventions
Pre operativeTrastuzumab, ABI-007 (Abraxane), Vinorelbine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Nov 2, 2026, 6:59 PM EST